Keurig Dr Pepper, Inc (NASDAQ:KDP) Given Average Recommendation of ...
π Analysts maintain an average 'Hold' rating on Keurig Dr Pepper with a consensus one-year price target of $32.47.
π Deutsche Bank lowered its price target to $28 and issued a 'hold' rating, contrasting with UBS Group's increase to $34 and 'buy' rating.
π° The stock opened at $31.25, trading between a fifty-two-week low of $24.88 and a high of $35.94.
π Q4 earnings beat with $0.39 EPS surpassing the $0.37 consensus estimate despite revenue of $3.98 billion missing the $7.23 billion expectation.
π Revenue grew 9.4% year-over-year to $3.98 billion, demonstrating solid top-line growth in the beverage sector.
π΅ The company reported a net margin of 10.81% and a return on equity of 10.51% for the quarter.
π Valuation metrics show a PE ratio of 23.15, a PEG ratio of 1.45, and a beta of 0.40 indicating lower volatility.
πΈ A quarterly dividend of $0.23 per share was paid on July 10th, resulting in a 2.9% annualized yield.
π KDP operates a vast network of manufacturing and distribution facilities serving retail, foodservice, and e-commerce markets.
π₯€ The company combines Keurig's single-serve coffee systems with a large portfolio of carbonated and noncarbonated drink brands.
- Keurig Dr Pepper reported EPS of $0.39 for the quarter, beating analyst consensus estimates by $0.02.
- Revenue increased by 9.4% year-over-year to reach $3.98 billion, indicating strong demand for the company's beverage portfolio.
- UBS Group raised its price objective from $32.00 to $34.00 and upgraded the rating to 'buy', while JPMorgan Chase increased its target to $33.00 with an 'overweight' rating.
- The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.72 and strong liquidity ratios of 2.12 (quick) and 2.31 (current).
- Shareholders received a quarterly dividend of $0.23 per share, contributing to a consistent annualized yield of 2.9%.
- Deutsche Bank Aktiengesellschaft cut its price target from $34.00 to $28.00 and assigned a 'hold' rating in a recent research note.
- BNP Paribas Exane downgraded the stock from 'underperform' to 'neutral' while setting a lower price target of $28.00.